Generation Bio (NASDAQ:GBIO) Stock Price Down 5.3% – Should You Sell?

Generation Bio Co. (NASDAQ:GBIO) shares traded down 5.3% on Monday . The stock traded as low as $5.05 and last traded at $5.05. 12,544 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 75,372 shares. The stock had previously closed at $5.33.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Canaccord Genuity Group increased their price target on shares of Generation Bio from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, August 18th. Wedbush lowered Generation Bio from an “outperform” rating to a “neutral” rating and set a $7.00 price objective on the stock. in a research report on Wednesday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Generation Bio in a research note on Wednesday, October 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $15.00 target price on shares of Generation Bio in a research report on Friday, November 7th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $10.67.

Generation Bio Price Performance

The business has a 50 day moving average of $5.76 and a 200 day moving average of $5.03. The firm has a market capitalization of $34.04 million, a price-to-earnings ratio of -0.54 and a beta of 1.96.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($3.18) by $2.36. The company had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $0.66 million. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%. As a group, equities analysts predict that Generation Bio Co. will post -1.75 EPS for the current year.

Institutional Trading of Generation Bio

Several hedge funds have recently added to or reduced their stakes in GBIO. Y Intercept Hong Kong Ltd acquired a new position in shares of Generation Bio in the 2nd quarter valued at approximately $47,000. Cantor Fitzgerald L. P. bought a new position in Generation Bio in the third quarter valued at approximately $606,000. Nuveen LLC acquired a new position in shares of Generation Bio in the first quarter valued at approximately $69,000. ADAR1 Capital Management LLC acquired a new position in shares of Generation Bio in the third quarter valued at approximately $136,000. Finally, Shay Capital LLC bought a new stake in shares of Generation Bio during the third quarter worth $64,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.